Rumpus VEDS

Rumpus Therapeutics was a biopharmaceutical company dedicated to developing treatments for rare and orphan diseases, with a primary focus on Vascular Ehlers-Danlos Syndrome (vEDS). The company's lead program, RT-001 (celiprolol), was a cardioselective beta-blocker with unique pharmacodynamic properties intended to reduce the risk of arterial rupture and dissection in vEDS patients. Rumpus was founded by industry veterans with experience in rare disease drug development and successfully advanced its lead candidate toward pivotal clinical trials. In 2020, the company was acquired by Aeglea BioTherapeutics, which sought to integrate the vEDS program into its portfolio of rare metabolic and genetic disease treatments.